These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19180514)

  • 1. Inhibition of p38: has the fat lady sung?
    Genovese MC
    Arthritis Rheum; 2009 Feb; 60(2):317-20. PubMed ID: 19180514
    [No Abstract]   [Full Text] [Related]  

  • 2. Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders.
    Goldstein DM; Kuglstatter A; Lou Y; Soth MJ
    J Med Chem; 2010 Mar; 53(6):2345-53. PubMed ID: 19950901
    [No Abstract]   [Full Text] [Related]  

  • 3. The as-yet unfulfilled promise of p38 MAPK inhibitors.
    Sweeney SE
    Nat Rev Rheumatol; 2009 Sep; 5(9):475-7. PubMed ID: 19710669
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.
    Cohen SB; Cheng TT; Chindalore V; Damjanov N; Burgos-Vargas R; Delora P; Zimany K; Travers H; Caulfield JP
    Arthritis Rheum; 2009 Feb; 60(2):335-44. PubMed ID: 19180516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-arthritic agents--SMi conference: trapping cytokines. 28-29 April 2003, London, UK.
    Evans R
    IDrugs; 2003 Jun; 6(6):548-51. PubMed ID: 12861982
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome.
    Ding C
    Curr Opin Investig Drugs; 2006 Nov; 7(11):1020-5. PubMed ID: 17117592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis.
    Zhang X; Huang Y; Navarro MT; Hisoire G; Caulfield JP
    J Clin Pharmacol; 2010 Sep; 50(9):1031-8. PubMed ID: 20100913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of the role of p38 mitogen-activated protein kinase inhibitors in patients with active rheumatoid arthritis.
    Li L; Li G; Yu C; Li Y
    Clin Rheumatol; 2013 Dec; 32(12):1697-702. PubMed ID: 23900576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy.
    Alten RE; Zerbini C; Jeka S; Irazoque F; Khatib F; Emery P; Bertasso A; Rabbia M; Caulfield JP
    Ann Rheum Dis; 2010 Feb; 69(2):364-7. PubMed ID: 19357113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SCIO-469 Scios Inc.
    Nikas SN; Drosos AA
    Curr Opin Investig Drugs; 2004 Nov; 5(11):1205-12. PubMed ID: 15573872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis.
    Pargellis C; Regan J
    Curr Opin Investig Drugs; 2003 May; 4(5):566-71. PubMed ID: 12833650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Go upstream, young man": lessons learned from the p38 saga.
    Hammaker D; Firestein GS
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1(Suppl 1):i77-82. PubMed ID: 19995751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinase inhibition--a new approach to the treatment of rheumatoid arthritis.
    Fox DA
    N Engl J Med; 2012 Aug; 367(6):565-7. PubMed ID: 22873537
    [No Abstract]   [Full Text] [Related]  

  • 14. p38 inhibition and not MK2 inhibition enhances the secretion of chemokines from TNF-α activated rheumatoid arthritis fibroblast-like synoviocytes.
    Dulos J; Wijnands FP; van den Hurk-van Alebeek JA; van Vugt MJ; Rullmann JA; Schot JJ; de Groot MW; Wagenaars JL; van Ravestein-van Os R; Smets RL; Vink PM; Hofstra CL; Nelissen RL; van Eenennaam H
    Clin Exp Rheumatol; 2013; 31(4):515-25. PubMed ID: 23558031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study.
    Balagué C; Pont M; Prats N; Godessart N
    Br J Pharmacol; 2012 Jun; 166(4):1320-32. PubMed ID: 22229697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERK activation by GM-CSF reduces effectiveness of p38 inhibitor on inhibiting TNFalpha release.
    Hua F; Henstock PV; Tang B
    Int Immunopharmacol; 2010 Jul; 10(7):730-7. PubMed ID: 20398804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
    Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR
    J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p38 mitogen-activated protein kinase (MAPK) in rheumatoid arthritis.
    Westra J; Limburg PC
    Mini Rev Med Chem; 2006 Aug; 6(8):867-74. PubMed ID: 16918493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinases as targets in rheumatoid arthritis.
    Tristano AG
    Int Immunopharmacol; 2009 Jan; 9(1):1-9. PubMed ID: 18848912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes.
    Riese RJ; Krishnaswami S; Kremer J
    Best Pract Res Clin Rheumatol; 2010 Aug; 24(4):513-26. PubMed ID: 20732649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.